INTERNATIONAL COLLABORATIVE EXERCISES (ICE) · any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city

INTERNATIONAL COLLABORATIVE

EXERCISES (ICE)

ICE

20

20

/1

Summary Report

ICE Round 2020/1

BIOLOGICAL SPECIMENS

International Collaborative Exercises (ICE)Summary report 2020/1- Biological Specimens

Copyright © 2021 UNODC

Page 1 of 60

ICE 2020/1-BS

Final summary report for ICE 2020/1 Biological Specimens Test Group

Original language: English

© United Nations, January 2021. All rights reserved, worldwide.

The designations employed and the presentation of material in this publication do not imply the expression of

any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any

country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries.

This publication has not been formally edited.



Page 2 of 60

ICE 2020/1-BS

Acknowledgements

The Laboratory and Scientific Section (LSS) of the UNODC, headed by Dr. Justice Tettey, wishes to express its appreciation and thanks to all laboratories for participating in the International Collaborative Exercises (ICE) round 2020/1. The valuable comments and contribution from the following members of the International Panel of Forensic Experts are gratefully acknowledged: Mr. Benoit Archambault, Health Canada, Canada Mr. Elvio Dias Botelho, Brazilian Federal Police, Brazil Prof. Heesun Chung, Sungkyunkwan University, Republic of Korea Prof. Niamh Nic Daéid, University of Dundee, Scotland, UK Mr. Scott Oulton, Drug Enforcement Administration, USA Ms. Catherine Quinn, Victoria Police, Australia Prof. Franco Tagliaro, University of Verona, Italy Dr. Angeline Tiong Whei Yap, Health Sciences Authority, Singapore In addition, LSS would like to acknowledge the valuable contribution of the Chemical Metrology Laboratory of the Health Sciences Authority, Singapore, for the provision of specific software used for the quantitative statistical calculations in the ICE programme. The ICE is coordinated by Ms. Yen Ling Wong, Scientific Affairs Officer, a staff member of LSS. The assistance and the contributions of the following LSS staff members are gratefully acknowledged. Dr. Conor Crean, Scientific Affairs Officer Mr. Joao Rodrigues, Scientific Affairs Officer Ms. Romana Luger, Research Assistant Dr. Gerd Krapf, Laboratory Technician Mr. Michael Bell, Laboratory Technician Ms. Mikaela Edwards, Laboratory Team Assistant For additional information or comments, please contact: Ms. Yen Ling Wong ICE Coordinator Scientific Affairs Officer Laboratory and Scientific Section UNODC, Vienna International Centre Wagramer Strasse 5, P.O. Box 500 A-1400, Vienna, AUSTRIA Email: [email protected]



Page 3 of 60

ICE 2020/1-BS

Contents

1. Codes and Abbreviations ..............................................................................................................................4

2. Test samples information .............................................................................................................................5

3. Introduction ..................................................................................................................................................6

4. Comments from the International Panel of Forensic Experts ......................................................................7

5. New Psychoactive Substances (NPS) reported .............................................................................................9

6. Summary of responses for Test Sample-1 ................................................................................................. 11




10. ANNEX 1: Participants’ results for Test Sample-1 ..................................................................................... 25






Page 4 of 60

ICE 2020/1-BS

1. Codes and Abbreviations (+) “positive” Indicates that the analyte is identified; for presumptive tests (e.g. colour reactions), indicates

that a positive reaction was obtained.

(-) “negative” Indicates that the analyte is not identified.

(ANP) Analysis not performed.

Tech Code Name

100 Agglutination techniques

110 Enzyme immunoassay techniques

120 Fluorescence polarization immunoassay

130 Radioimmunoassay

140 Colorimetric reactions

141 Marquis test

142 Cobalt thiocyanate test

150 Thin layer chromatography (TLC)

160 High/ultra high performance liquid chromatography with ultraviolet-visible spectroscopy (HPLC/UPLC)

161 High/ultra high performance liquid chromatography with diode array detection (HPLC-DAD or UPLC-DAD)*

170 Gas chromatography with nitrogen-phosphorous detection (GC-NPD)

171 Gas chromatography with flame ionization detection (GC-FID)

172 Gas chromatography with electron capture detection (GC-ECD)

180 Gas chromatography with mass spectrometry (GC-MS)

190 Fourier transform infrared spectrometry (FTIR)

200 Spectrophotometry (visible, UV)

210 Others

211 Nuclear magnetic resonance spectroscopy (NMR)

220 Microcrystal test

230 Liquid chromatography with mass spectrometry (LC-MS)

231 Liquid chromatography with tandem mass spectrometry (LC-MS/MS)

*similar to 160



Page 5 of 60

ICE 2020/1-BS

2. Test samples information The following four (4) test samples for the Biological Specimens test group were prepared by a private company under subcontract with the Laboratory and Scientific Section, UNODC: Test Sample-1 (BS-1) BS-1 was a blank urine test sample containing no substances from the ICE menu. The urine was dispensed in 25 mL aliquots and lyophilised. Test Sample-2 (BS-2) To prepare BS-2, urine was spiked with an ethanolic solution of metamfetamine hydrochloride and a methanolic solution of amfetamine sulphate to achieve final concentrations of 920 ng base/mL and 345 ng base/mL, respectively. The spiked urine was dispensed in 25 mL aliquots and lyophilised. Test Sample-3 (BS-3) To prepare BS-3, urine was spiked with an methanolic solution of 11-nor-∆9-THC-9-carboxylic acid to achieve a final concentration of 345 ng base/mL. The spiked urine was dispensed in 25 mL aliquots and lyophilised. Test Sample-4 (BS-4) To prepare BS-4, urine was spiked with an aqueous solution of morphine sulphate to achieve a final concentration of 920 ng base/mL. The spiked urine was dispensed in 25 mL aliquots and lyophilised. All test samples were prepared from urine free of all major groups of abused drugs. Metabolites of caffeine may be present. No preservatives were added to the urine samples. All analytes spiked into the test samples were commercially sourced reference standards.



Page 6 of 60

ICE 2020/1-BS

3. Introduction An important element of the UNODC International Quality Assurance Programme (IQAP) is the

implementation of the International Collaborative Exercises (ICE). The exercises allow laboratories, from both

developing and developed countries to continuously monitor their performance in drug testing on a truly

global scale. This report provides information on analytical results of laboratories participating in the Biological

Specimens (BS) test group. In order to maintain confidentiality, the participating laboratories have been

assigned random “Round Codes”, which change every round.

The analytical results returned by laboratories participating in ICE are evaluated by UNODC and a confidential

report is provided to each laboratory on its own performance. The overall analytical results are reviewed by

the UNODC’s International Panel of Forensic Experts which oversees the implementation of these exercises,

and offers guidance and support in addressing relevant quality issues. The exercises provide an overview of

the performance and capacity of participating laboratories and enable UNODC to tailor technical support in

the laboratory sector for greatest impact.

The ICE programme is a UNODC mandated activity and is implemented through regular budget funds and

through the UNODC Global Scientific and Forensic Programme – Support Project (GLOU54), which

operationalizes the forensic aspects of the UNODC Thematic Programme on Research, Trend Analysis and

Forensics". Figure 1 shows the growth of the programme in recent years for both the Seized Materials (SM)

and the Biological Specimens (BS) test groups.

Note: Reduced participation rate in round 2020/1 resulted from the challenges arising from the COVID-19

pandemic.

Figure 1. Growth of the ICE programme (as of 23 December 2020)

66 62

77

94100 102

116

129 132 131

151159

179173

184 185

204 204 204195

222217

179

26 2733

4237

4754

62 58 6272 74

86 9095 92 96 97 93

87

101106

83

0

50

100

150

200

250

No

. of

lab

ora

tori

es

ICE round

SM BS



Page 7 of 60

ICE 2020/1-BS

4. Comments from the International Panel of Forensic Experts

4.1 Participation of Laboratories in ICE round 2020/1

In the 2020/1 round of the ICE programme, results were submitted within both the Seized Materials (SM)

and Biological Specimens (BS) test groups by 215 laboratories in 59 countries. Within the BS test group,

results were submitted by 83 laboratories from 39 countries and within the SM test group, there were 179

participating laboratories from 51 countries. The reduced participation rate of this round is mainly due to

shipping restrictions to a number of countries experiencing on-going COVID-19 pandemic. On an

exceptional basis, laboratories could request test samples for both rounds, i.e. 2020/1 and 2020/2 to be

sent together. However, results submitted will not be included in this summary report.

4.2 Qualitative Analysis

The analytical techniques most commonly used for screening of test samples in the BS test group were

immunoassays (59% of participants). GC-MS (73% of participants) was the most commonly used technique

for identification/confirmation of the components in the test samples, followed by LC-MS/MS (47% of

participants). The results for the qualitative identification of the sample components in the BS test group,

the number of false positive/negative results and the analyses not performed are shown in Table 1.

Table 1. Performance of participants in the 2020/1 round of ICE.

Test sample BS-1

(Blank)

BS-2 BS-3 BS-4

(Metamfetamine) (Amfetamine) (11-nor-∆9-THC-9-carboxylic acid)

(Morphine)

Correct identification by participants

90.4% 95.2% 81.9%

88.0% 85.5% At least 1 component: 97.6%

Number of false positives

4 4 3 8

Number of false negatives

0 2 2 4

Number of analyses not performed

4 0 8 8

Overall, the participants performed better in this round compared to the previous round with at least 85%

of participants correctly identifying each test sample. A total of 74% of participants were able to identify

all 4 test samples correctly. It is encouraging to note that a significant reduction in the total number of false

positives and false negatives reported was also observed. In addition, the number of analyses not

performed has also decreased from the previous round. Nonetheless, laboratories reporting false positive

or false negative results should investigate the reasons for this and corrective actions should be taken as

soon as possible in order to continuously improve performance. ICE participants are reminded that test

samples can contain any of the substances in the ICE menu and as such if methods are available, all

substances should be considered.



Page 8 of 60

ICE 2020/1-BS

4.3 Quantitative Analysis

The test samples in the BS group for the 2020/1 round of ICE contained a total of four components and 36

(43%) laboratories performed quantification. Of these laboratories, it is encouraging to note that 92% of

laboratories quantified at least two components and 58% performed quantification of all four components.

GC-MS, used by 58% of participants, was the most commonly used technique for quantitation, followed by

LC-MS/MS, which was used by 42% of participants. z-Scores obtained by participants in quantification are

shown in Table 2 below (percentage + no. of labs indicated).

Table 2. Quantitative performance of participants in the 2020/1 round of ICE.

In general, the performance of laboratories improved with more laboratories achieving acceptable z-scores.

According to the recommendations in ISO 13528:2015, an unacceptable z-score is considered to give an

action signal and a questionable z-score is considered to give a warning signal. A single action signal or

warning signal in two successive rounds shall be taken that an anomaly has occurred that requires

investigation. Participants with z-scores outside acceptable limits should review their quantification

procedures as soon as possible.

Only 1 laboratory, PYGPFU, obtained a single action signal or warning signal in the two successive rounds

of 2019/2 and 2020/1. This laboratory shall take this as anomaly, which requires further investigation.

Of the 4 laboratories that obtained a single action or warning signal in ICE rounds 2019/1 and 2019/2, 1

laboratory improved, 2 laboratories did not participate in round 2020/1 while 1 laboratory obtained action

or warning signals in this round: PYGPFU.

Laboratories that need to perform quantitation routinely are encouraged to participate regularly in

external proficiency testing or collaborative exercises such as the ICE programme. This will enable

laboratories to assess the quality of their quantitative methods through the z-score values obtained.

Laboratories reporting false positive or false negative results should investigate the root causes and

corrective actions taken promptly in order to continuously improve performance. Participation in the ICE

programme also helps in monitoring the effect of corrective actions.

z-score

Test sample

BS-2 (920 ng/mL

Metamfetamine)

BS-2 (345 ng/mL

Amfetamine)

BS-3 (345 ng/mL

11-nor-∆9-THC-9-carboxylic acid)

BS-4 (920 ng/mL Morphine)

|z| ≤ 2.00, acceptable

93.3% (28) 82.8% (24) 92.6% (25) 81.2% (26)

2.00 < |z| < 3.00, questionable

6.7% (2) 6.9% (2) 3.7% (1) 12.5% (4)

|z| ≥ 3.00, unacceptable

0.0% (0) 10.3% (3) 3.7% (1) 6.3% (2)



Page 9 of 60

ICE 2020/1-BS

5. New Psychoactive Substances (NPS) reported During the 2020/1 round of ICE, participating laboratories provided information on NPS that had been identified in their laboratories. In total there were 153 reports of 110 substances and the most commonly reported substances were synthetic cannabinoids (29%) followed by phenethylamines (20%) as shown in Figure 2.

Figure 2. Distribution of classes of NPS reported by ICE laboratories during the 2020/1 round of ICE

In terms of the mode of action of the NPS reported by ICE participants, the predominant substances reported were synthetic cannabinoid receptor agonists (28%) followed by stimulants (26%), while 23% were hallucinogens as shown in Figure 3.

Figure 3. Distribution of NPS reported by ICE participants in the 2020/1 round of ICE according to the

mode of action

1%

19%

11%

20%

1%1%

29%

13%

5%

Aminoindanes

Other substances

Phencyclidine-type-substances

Phenethylamines

Piperazines

Plant-based substances

Synthetic cannabinoids

Synthetic cathinones

Tryptamines

11%

23%

7%

4%26%

28%

1%

Dissociative

Hallucinogen

Synthetic opioid

Sedative hypnotic

Stimulant

Synthetic cannabinoid

N/A



Page 10 of 60

ICE 2020/1-BS

The substances most often reported by ICE participants were Ketamine, 5F-MDMB-PICA and MDMB-

4en-PINACA. While ketamine is currently not under international control, 5F-MDMB-PICA was placed in

schedule II of the 1971 convention effective 3rd November 2020. MDMB-4en-PINACA was recommended

by the WHO to be placed in schedule II of the 1971 convention and this decision will be voted upon at

the 64th session of the Commission on Narcotic Drugs in 2021.

Name Convention Schedule Effective date of

international control

Ketamine 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one

Currently not under international control

5F-MDMB-PICA methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate

1971 II 3rd November 2020

MDMB-4en-PINACA methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate

Recommended for scheduling in April 2021

For further details on these substances and others reported to the UNODC Early Warning Advisory, ICE

participants can log on to the UNODC ICE portal, www.unodc.org/lss, and select the icon for the Early

Warning Advisory on New Psychoactive substances as shown below.



Page 11 of 60

ICE 2020/1-BS

6. Summary of responses for Test Sample-1

The summary of responses of all 83 participating laboratories for the identification of BS-1:

Correct identification of Test Sample-1:

Test Sample-1 was a blank test sample containing no substances from the BS ICE menu

False positives for Test Sample-1 (technique(s) used):

Analysis not performed for Test Sample-1:

JXLWWW, NJYQDQ, PQCCX9 and S686FB

Frequency of use of screening, identification and quantification techniques:

Test Sample 1: Response Summary

No of Participants: 83 (Qualitative); 0 (Quantitative)

Technique 100 110 120 140 150 160 161 170 180 210 230 231

Screening (No.) 1 46 2 1 1 1 0 0 15 1 5 13

(%) 1.2 55.4 2.4 1.2 1.2 1.2 0.0 0.0 18.1 1.2 6.0 15.7

Identification (No.) 0 5 1 0 6 3 4 1 61 0 11 39

(%) 0.0 6.0 1.2 0.0 7.2 3.6 4.8 1.2 73.5 0.0 13.3 47.0

Quantification (No.) 0 0 0 0 0 0 0 0 0 0 0 0

(%) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Number of laboratories Percentage

75 90.4%

Round Code Substance Reported Tech Code GYUZYX Methylecgonine 180 QQPBQ3 gamma-Hydroxybutyric acid (GHB) 180 VZZCZZ gamma-Hydroxybutyric acid (GHB) 230

XA5WMW Diacetylmorphine, epinephrine,

morphine, nordazepam, temazepam

180



Page 12 of 60

ICE 2020/1-BS





* possible transcription error

False negatives for Test Sample-2 with respect to Metamfetamine (and/or metabolite)

(technique(s) used):

Round Code Tech Code

REAZAR 180 XA5WMW 180

Analysis not performed for Test Sample-2 with respect to Metamfetamine (and metabolite):

All participating laboratories carried out analysis for Metamfetamine (and/or metabolite)




Technique 100 110 120 140 150 160 161 170 180 210 230 231

Screening (No.) 1 46 2 1 1 1 0 0 15 1 5 13

(%) 1.2 55.4 2.4 1.2 1.2 1.2 0.0 0.0 18.1 1.2 6.0 15.7


(%) 0.0 6.0 1.2 0.0 7.2 3.6 4.8 1.2 73.5 0.0 13.3 47.0


(%) 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 41.9 0.0 6.5 38.7

Substance Name Number of laboratories Percentage Metamfetamine 79 95.2%

Amfetamine 68 81.9% At least one component 81 97.6%

Round Code Substance Reported Tech Code

3HHHFH Morphine 231

EMDIVE Methadone, 6-monoacetylmorphine,

morphine

180

X2IWBU MDMA* 231

XA5WMW Benzoylecgonine, cocaine,

diacetylmorphine, morphine,

nordazepam, temazepam

180



Page 13 of 60

ICE 2020/1-BS

Z-Score Report per Sample per Substance:

Round: 2020/1

Substance: BS-2; Metamfetamine

-2.5

8

-1.9

0 -1.3

6

-1.2

4

-1.2

2

-1.2

0 -0.8

0

-0.4

7

-0.4

1

-0.2

4

-0.1

9

-0.1

0

-0.0

7

-0.0

6

0.0

3

0.0

6

0.0

8

0.2

9

0.3

0

0.4

1

0.4

1

0.4

5

0.4

9

0.6

2 0.8

9

0.9

0

0.9

4

1.6

9 1.9

7

2.6

1

-4.00

-3.00

-2.00

-1.00

0.00

1.00

2.00

3.00

4.00

VZZ

CZZ

8T8

8D

Y

YBX

JLV

J4TW

7Y

7B

JIM

Y

DC

GD

XG

MZ1

VW

F

OJI

RJJ

ATV

RV

M

5X

RK

WM

5Q

55

XW

7O

QC

KC

GA

LBA

U

5M

R6

TM

T99

ZDI

2P

U2

G2

49

93

91

Q6

MZS

I

S68

6FB

ZJFF

FJ

NJY

QD

Q

X2

IWB

U

HX

3H

HZ

3H

HH

FH

C6

P3

ZC

83

4U

F9

QQ

PB

Q3

XI4

34

E

GQ

D9

11

PYG

PFU

Z-scores can be interpreted by participants in line with ISO 13528:2015*, section 9.4.2 as follows: IzI ≤ 2.00 is considered to be acceptable 2.00 < IzI < 3.00 is considered to be questionable (or warning signal) IzI ≥ 3.00 is considered to be unacceptable (or action signal)

A single action signal or warning signal in two successive rounds shall be taken that an anomaly has occurred that requires investigation.

Robust mean: 876 ng/mL Robust SD: 304 ng/mL Robust CV%: 34.7%

Prepared conc.: 920 ng/mL Max reported: 1670 ng/mL Min reported: 90.4 ng/mL No of labs: 30



Page 14 of 60

ICE 2020/1-BS


Round: 2020/1

Substance: BS-2; Amfetamine

-2.2

7 -1.7

6 -1.1

9

-0.9

5

-0.9

5

-0.8

1

-0.5

8

-0.4

5

-0.4

2

-0.3

9

-0.3

9

-0.3

6

-0.3

0

-0.2

6

-0.1

0

-0.0

9

-0.0

8

0.1

8

0.1

9

0.2

2 0.5

4

0.6

6

0.6

6

0.7

3 1.1

6

2.3

9

3.9

5

4.5

8

5.3

7

-4.00

-3.00

-2.00

-1.00

0.00

1.00

2.00

3.00

4.00

VZZ

CZZ

8T8

8D

Y

7B

JIM

Y

J4TW

7Y

5Q

55

XW

MZ1

VW

F

OJI

RJJ

Q6

MZS

I

5X

RK

WM

ATV

RV

M

HX

3H

HZ

2P

U2

G2

S68

6FB

5M

R6

TM

T99

ZDI

83

4U

F9

X2

IWB

U

3H

HH

FH

JXLW

WW

DC

GD

XG

XI4

34

E

7O

QC

KC

NJY

QD

Q

49

93

91

QQ

PB

Q3

GQ

D9

11

PYG

PFU

ZJFF

FJ

C6

P3

ZC







Page 15 of 60

ICE 2020/1-BS




Page 16 of 60

ICE 2020/1-BS

Z-Scores for Test Sample-2

Code

Metamfetamine

Code

Amfetamine

Concentration (ng/mL)

Deviation from robust

average (ng/mL)

z-score Concentration (ng/mL)


average (ng/mL)

z-score

VZZCZZ 90 -786 -2.58 VZZCZZ 22 -324 -2.27

8T88DY 300 -576 -1.90 8T88DY 94 -252 -1.76

YBXJLV 462 -414 -1.36 7BJIMY 177 -170 -1.19

J4TW7Y 500 -376 -1.24 J4TW7Y 210 -136 -0.95

7BJIMY 504 -372 -1.22 5Q55XW 210 -136 -0.95

DCGDXG 511 -365 -1.20 MZ1VWF 230 -116 -0.81

MZ1VWF 632 -244 -0.80 OJIRJJ 263 -83 -0.58

OJIRJJ 733 -143 -0.47 Q6MZSI 281 -65 -0.45

ATVRVM 750 -126 -0.41 5XRKWM 285 -61 -0.42

5XRKWM 803 -73 -0.24 ATVRVM 290 -56 -0.39

5Q55XW 818 -58 -0.19 HX3HHZ 290 -56 -0.39

7OQCKC 846 -30 -0.10 2PU2G2 295 -51 -0.36

GALBAU 854 -22 -0.07 S686FB 303 -43 -0.30

5MR6TM 859 -17 -0.06 5MR6TM 309 -37 -0.26

T99ZDI 885 9 0.03 T99ZDI 332 -14 -0.10

2PU2G2 894 18 0.06 834UF9 333 -13 -0.09

499391 900 24 0.08 X2IWBU 334 -12 -0.08

Q6MZSI 965 89 0.29 3HHHFH 371 25 0.18

S686FB 966 90 0.30 JXLWWW 373 27 0.19

ZJFFFJ 1000 124 0.41 DCGDXG 378 32 0.22

NJYQDQ 1000 124 0.41 XI434E 423 77 0.54

X2IWBU 1014 138 0.45 7OQCKC 440 94 0.66

HX3HHZ 1025 149 0.49 NJYQDQ 440 94 0.66

3HHHFH 1066 190 0.62 499391 450 104 0.73

C6P3ZC 1148 272 0.89 QQPBQ3 512 166 1.16

834UF9 1150 274 0.90 GQD911 688 342 2.39

QQPBQ3 1163 287 0.94 PYGPFU 910 564 3.95

XI434E 1389 513 1.69 ZJFFFJ 1000 654 4.58

GQD911 1475 599 1.97 C6P3ZC 1113 767 5.37

PYGPFU 1670 794 2.61



Page 17 of 60

ICE 2020/1-BS





False negatives for Test Sample-3 with respect to 11-nor-∆9-THC-9-carboxylic acid (technique(s) used):


DKQBOL 180, 231 PQCCX9 231

Analysis not performed for Test Sample-3 with respect to 11-nor-∆9-THC-9-carboxylic acid:

658B75, 8T88DY, ATVRVM, GYZBJG, HWWFLB, QAWYAR, REAZAR and SEWUD2




Technique 100 110 120 140 150 160 161 170 180 210 230 231

Screening (No.) 1 46 2 1 1 1 0 0 15 1 5 13

(%) 1.2 55.4 2.4 1.2 1.2 1.2 0.0 0.0 18.1 1.2 6.0 15.7


(%) 0.0 6.0 1.2 0.0 7.2 3.6 4.8 1.2 73.5 0.0 13.3 47.0


(%) 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 55.6 0.0 3.7 25.9

Substance Name Number of laboratories Percentage 11-nor-∆9-THC-9-carboxylic acid 73 88.0%


3HHHFH Morphine 231

PLCVCA Paracetamol 231

XA5WMW Benzoylecgonine, cocaine,

diacetylmorphine, morphine,

nordazepam

180



Page 18 of 60

ICE 2020/1-BS


Round: 2020/1

Substance: BS-3; 11-nor-∆9-THC-9-carboxylic acid

-2.9

5

-1.8

6

-1.0

9

-1.0

4

-1.0

3

-0.9

7 -0.5

9

-0.3

9

-0.3

6

-0.3

3

-0.3

3

-0.2

6

-0.2

2

-0.1

2

-0.1

1

0.1

5

0.3

6

0.4

4

0.4

8

0.5

0

0.6

0

0.8

1 1.0

9

1.1

0

1.3

1 1.6

8

6.2

3

-4.00

-3.00

-2.00

-1.00

0.00

1.00

2.00

3.00

4.00

XA

5W

MW

ZJFF

FJ

Q6

MZS

I

J4TW

7Y

GQ

D9

11

XI4

34

E

OJI

RJJ

JXLW

WW

DC

GD

XG

83

4U

F9

NJY

QD

Q

QQ

PB

Q3

3H

HH

FH

7O

QC

KC

S68

6FB

T99

ZDI

X2

IWB

U

MZ1

VW

F

9R

5K

1I

49

93

91

HX

3H

HZ

5X

RK

WM

C6

P3

ZC

2P

U2

G2

VZZ

CZZ

YBX

JLV

PYG

PFU



Robust mean: 270 ng/mL Robust SD: 91.5 ng/mL Robust CV%: 33.9%

Prepared conc.: 345 ng/mL Max reported: 840 ng/mL Min reported: 0.02 ng/mL



Page 19 of 60

ICE 2020/1-BS




Page 20 of 60

ICE 2020/1-BS


Code

11-nor-∆9-THC-9-carboxylic acid



average (ng/mL)

z-score

XA5WMW 0.02 -270 -2.95

ZJFFFJ 100 -170 -1.86

Q6MZSI 170 -100 -1.09

J4TW7Y 175 -95 -1.04

GQD911 176 -94 -1.03

XI434E 181 -89 -0.97

OJIRJJ 216 -54 -0.59

JXLWWW 234 -36 -0.39

DCGDXG 237 -33 -0.36

834UF9 240 -30 -0.33

NJYQDQ 240 -30 -0.33

QQPBQ3 246 -24 -0.26

3HHHFH 250 -20 -0.22

7OQCKC 259 -11 -0.12

S686FB 260 -10 -0.11

T99ZDI 284 14 0.15

X2IWBU 303 33 0.36

MZ1VWF 310 40 0.44

9R5K1I 314 44 0.48

499391 316 46 0.50

HX3HHZ 325 55 0.60

5XRKWM 344 74 0.81

C6P3ZC 370 100 1.09

2PU2G2 371 101 1.10

VZZCZZ 390 120 1.31

YBXJLV 424 154 1.68

PYGPFU 840 570 6.23



Page 21 of 60

ICE 2020/1-BS





False negatives for Test Sample-4 with respect to Morphine (technique(s) used):


DKQBOL 180, 231 GTGYJT 110, 150

UUBWFO 230 XLVKDV 150, 180

Analysis not performed for Test Sample-4 with respect to Morphine:

658B75, 8T88DY, DCG2M5, GYUZYX, GYZBJG, HWWFLB, OJIRJJ and SEWUD2




Technique 100 110 120 140 150 160 161 170 180 210 230 231

Screening (No.) 1 46 2 1 1 1 0 0 15 1 5 13

(%) 1.2 55.4 2.4 1.2 1.2 1.2 0.0 0.0 18.1 1.2 6.0 15.7


(%) 0.0 6.0 1.2 0.0 7.2 3.6 4.8 1.2 73.5 0.0 13.3 47.0


(%) 0.0 3.1 0.0 0.0 0.0 0.0 0.0 0.0 50.0 0.0 9.4 28.1

Substance Name Number of laboratories Percentage Morphine 71 85.5%


AE71EE Hydromorphone 231

EMDIVE Codeine, 6-monoacetylmorphine 180

GALBAU Lidocaine 180, 231

GTGYJT Codeine 110, 150

GYUZYX 6-Monoacetylmorphine 161

J4TW7Y Asenapine 180, 231

Q6MZSI Hydromorphone 180, 231

XA5WMW Diacetylmorphine, epinephrine,

nordazepam, temazepam

180



Page 22 of 60

ICE 2020/1-BS


Round: 2020/1

Substance: BS-4; Morphine

-3.3

0 -2.9

8

-2.9

2

-2.1

2

-1.2

1 -0.7

9

-0.7

8

-0.6

2

-0.5

4

-0.4

5

-0.4

1

-0.3

3

-0.1

6

-0.1

0

0.0

1

0.0

3

0.0

7

0.0

9

0.2

9

0.3

7

0.3

9

0.4

4

0.5

2

0.6

1

0.7

0

0.7

5

0.8

1

0.8

9

0.8

9

1.5

6

2.4

0

3.0

1

-4.00

-3.00

-2.00

-1.00

0.00

1.00

2.00

3.00

4.00

XA

5W

MW

REA

ZAR

GA

LBA

U

7B

JIM

Y

J4TW

7Y

49

93

91

7O

QC

KC

YBX

JLV

VZZ

CZZ

XI4

34

E

QQ

PB

Q3

PYG

PFU

C6

P3

ZC

S68

6FB

HX

3H

HZ

GX

AX

XX

2P

U2

G2

5M

R6

TM

X2

IWB

U

MZ1

VW

F

NJY

QD

Q

5Q

55X

W

T99

ZDI

ZJFF

FJ

5X

RK

WM

83

4U

F9

JXLW

WW

9R

5K

1I

Q6

MZS

I

QK

N0

0I

DC

GD

XG

GQ

D9

11







Page 23 of 60

ICE 2020/1-BS




Page 24 of 60

ICE 2020/1-BS


Code

Morphine



average (ng/mL)

z-score

XA5WMW 1 -787 -3.30

REAZAR 78 -710 -2.98

GALBAU 93 -695 -2.92

7BJIMY 282 -506 -2.12

J4TW7Y 500 -288 -1.21

499391 600 -188 -0.79

7OQCKC 602 -186 -0.78

YBXJLV 641 -147 -0.62

VZZCZZ 660 -128 -0.54

XI434E 681 -107 -0.45

QQPBQ3 690 -98 -0.41

PYGPFU 710 -78 -0.33

C6P3ZC 750 -38 -0.16

S686FB 763 -25 -0.10

HX3HHZ 790 2 0.01

GXAXXX 796 8 0.03

2PU2G2 805 17 0.07

5MR6TM 810 22 0.09

X2IWBU 858 70 0.29

MZ1VWF 877 89 0.37

NJYQDQ 880 92 0.39

5Q55XW 893 105 0.44

T99ZDI 913 125 0.52

ZJFFFJ 933 145 0.61

5XRKWM 955 167 0.70

834UF9 966 178 0.75

JXLWWW 980 192 0.81

9R5K1I 1000 212 0.89

Q6MZSI 1001 213 0.89

QKN00I 1160 372 1.56

DCGDXG 1360 572 2.40

GQD911 1505 717 3.01



Page 25 of 60

ICE 2020/1-BS

10. ANNEX 1: Participants’ results for Test Sample-1

Identified substances for Test Sample 1

Code Identified Substances

7BJIMY None

7DD9DQ None

7V7K74 No

C6P3ZC none

CYYURR -

GTGYJT negative

GYUZYX Methylecgonine

GYZBJG No common basic and acid drugs were detected in sample 2020/1/BS-1.

HWWFLB NONE

HX3HHZ -

J4TW7Y NONE

MZ1VWF no determine

PLCVCA NO DRUGS DETECTED

Q6MZSI No drugs detected

QHSF3F NONE

QQPBQ3 GHB

QSF8QS None Detected

SEWUD2 -

XA5WMW Diacetylmorphine, epinephrine, Nordazepam

XLVKDV no

YXWLMW BLANK SAMPLE

ZJFFFJ none



Page 26 of 60

ICE 2020/1-BS

Statement of findings for Test Sample 1

Code [blank sample]

0UAAAS

11101C

2PU2G2 No drugs detected.

33W3VV The urine sample analyzed did not detect the presence of controlled drugs.

3HHHFH Common Drugs or Poisons Not Detected

3XRTAK None of the drugs, within the scope of testing, were detected in the urine specimen

43A63W

4464E4 No drug was detected by all the methods (both screening and analytical techniques that was used)

499391 Negative

5H6VOU No drug schedule was detected in BS-1 sample.

5MR6TM Negative

5Q55XW BS-1 is negative for drugs Amphetamine Types Stimulants,Cannabinoids, Opiates & Ketamine

5XRKWM

658B75 Common drugs not detected

7BJIMY No drugs were detected in BS-1, 2020/1 exercise

7DD9DQ In sample BS-1 none drug was detected

7HRXA5

7OQCKC

7V7K74 No drugs detected in BS-1 sample.

834UF9

8T88DY

9R5K1I

A4AQON

AE71EE No drugs was detected in this urine sample using available methods

AIWSV2

ATVRVM

BFKQKL

C6P3ZC no consumer

CMPLP5

CYYURR We not found contain controlled drugs in BS-01

DCG2M5 No common drugs were detected in sample 2020/1/BS-1.

DCGDXG Negative

DKQBOL Examination and analyses performed on 2020/1/BS-1 did not reveal the presence of substances of toxicological significance

EMDIVE



Page 27 of 60

ICE 2020/1-BS

Code [blank sample]

FKHAKK

GALBAU We didn't find any of the drugs present in the ICE menu, in concentrations above our instruments' cutoff. But we found caffeine in the sample.

GEIYZE

GQD911

GTGYJT 2020/1/BS-1urine negative result.

GXAXXX Drugs were not detected in 2020/1/BS-1.

GYUZYX It was detected the presence of Methylecgonine in the sample analysed.


HFZNVM The substances that were tested are not present.

HJBJJZ Not detected.

HWWFLB SAMPLE 2020/1/BS-1 FOUND NOT TO CONTAIN ANY DRUGS

HX3HHZ -

IY7GAM

IZHTGD

J4TW7Y No drug found from those investigated.

JXLWWW

MGYQGS En la muestra analizada no se detectó cocaína, cannabinoides, opiáceos, opioides, benzodiacepinas, fetoniazinas, antidepresivos tricíclicos, anfetaminas o sus metabolitos.

MHHRMM

MZ1VWF No determined any drugs from the list.

NJYQDQ

OJIRJJ Test sample 2020/1/BS-1 does not contain controlled drugs (Metamfetamine, Amfetamine, 11- nor-∆9-THC-9-carboxylic acid and Benzoylecgonine), therefore Negative for Screening and Confirmatory analyses.

PLCVCA NO DRUGS DETECTED WITH THE METHODS USED

PQCCX9 BS1 broken in transit

PYGPFU

Q6MZSI No drugs detected in this sample BS-1

QAWYAR

QHSF3F CAFFEINE

QKN00I No se ha identificado ninguna de las sustancias de interes toxicológico investigadas

QQPBQ3 Identification by GC-MS.

QSF8QS Urine Drugs Screen - Drugs Not Detected

REAZAR

RLFVLF Common drugs not found.

S686FB

SEWUD2 no common drugs detected

SRDSSE



Page 28 of 60

ICE 2020/1-BS

Code [blank sample]

T99ZDI

UUBWFO

VZZCZZ

W4HPDB

W6QSWO No targeted drugs detected

W72LJ2

X2IWBU

XA5WMW Diacetylmorphine was detected in the sample.

XI434E this person did not consumed drugs or psychotropic substances

XLVKDV

YBXJLV None of the substances refered from the list were unable to identify

YN9NMH

YXWLMW NO DRUG FOUND

ZJFFFJ



Page 29 of 60

ICE 2020/1-BS

Identification methods for Test Sample 1

Analytical Technique Codes

Code 100 110 120 140 150 160 161 170 180 230 231 210

0UAAAS SI I I

11101C S I UHPLC-QTOF

2PU2G2 I I SI

33W3VV SI I

3HHHFH S I I

3XRTAK I SI

43A63W I S Immunochromatography

4464E4 S SI I S GC-MS/MS

499391 S I

5H6VOU I I I S Immunochromatography

5MR6TM S I I LC/ TOF/ MS

5Q55XW S I I I

5XRKWM S I I

658B75 I

7BJIMY SI I SI

7DD9DQ SI SI

7HRXA5 SI

7OQCKC S I

7V7K74 I

834UF9 S I SI

8T88DY I

9R5K1I SI SI

A4AQON SI S Immunochromatographic test

AE71EE I S Immunochromatography

AIWSV2 I

ATVRVM I I S

BFKQKL S I I

C6P3ZC SI

CMPLP5 I I S Immunoassay Techniques

CYYURR S I I

DCG2M5 SI

Legend: S ... used for Screening I ... used for Identification SI ... used for both



Page 30 of 60

ICE 2020/1-BS

Code 100 110 120 140 150 160 161 170 180 230 231 210

DCGDXG S SI SI I

DKQBOL I I

EMDIVE S I

FKHAKK I S Immunoassy

GALBAU SI I

GEIYZE S I

GQD911 S I

GTGYJT SI I S biochipRandox

GXAXXX S I

GYUZYX S I SI

GYZBJG I

HFZNVM I

HJBJJZ I

HWWFLB SI

HX3HHZ SI I

IY7GAM S I SI

IZHTGD S I I

J4TW7Y S I SI

MGYQGS I I

MHHRMM S I I

MZ1VWF S I SI

NJYQDQ S I S

OJIRJJ I S DTK

PLCVCA S I

PQCCX9 SI

PYGPFU I S immunochromatographic test

Q6MZSI S I I

QAWYAR I LC-QTOF

QHSF3F S I I

QKN00I S I I

QQPBQ3 S I

QSF8QS I

REAZAR S I

RLFVLF S I

S686FB I I I Kinetic Interactions of Microparticles

SEWUD2 SI

SRDSSE SI I



Page 31 of 60

ICE 2020/1-BS

Code 100 110 120 140 150 160 161 170 180 230 231 210

T99ZDI S I I I

UUBWFO I I S Cobas

VZZCZZ SI

W4HPDB S I I

W6QSWO SI

W72LJ2 SI

X2IWBU S I I

XA5WMW S I

XI434E S I I

XLVKDV I I

YBXJLV S I

YN9NMH S I SI

YXWLMW SI

ZJFFFJ I SI Dipro Drug lab screen



Page 32 of 60

ICE 2020/1-BS

11. ANNEX 2: Participants’ results for Test Sample-2 Identified substances for Test Sample 2


0UAAAS AMPHETAMINES

11101C Metamfetamine & Amfetamine

2PU2G2 amfetamine, metamfetamine

33W3VV Anfetamine and Metanfetamine

3HHHFH Amphetamine, Methylamphetamine, Morphine(total)

3XRTAK Methamphetamine

43A63W amfetamine and metamfetamine

4464E4 Amphetamine, Methamphetamine

499391 Amphetamine, Metamphetamine

5H6VOU Amfetamine and metamfetamine

5MR6TM Methamphetamine and Amphetamine

5Q55XW Amphetamine & Methamphetamine

5XRKWM Amphetamine and Methamphetamine

658B75 Amfetamine and metamfetamine

7BJIMY Amfetamine and Metamfetamine

7DD9DQ Anfetamine and metanfetamine

7HRXA5 Metamfetamine

7OQCKC amfetamine, metamfetamine

7V7K74 Amphetamine and methamphetamine.

834UF9 amfetamine, metamfetamine

8T88DY Amphetamine Methanphetamine

9R5K1I D-amfetamine + S-methylamphetamine

AE71EE amphetamine, methamphetamine

AIWSV2 Amfetamine, Metamfetamine

ATVRVM Amphetamine and Methamphetamine

BFKQKL Metamfetamine

C6P3ZC AMP MA

CMPLP5 Amfetamine and Metamfetamine

CYYURR Metamfetame and Amfetamine

DCG2M5 Amfetamine and Metamfetamine

DCGDXG amphetamine, metamphetamine

DKQBOL Amfetamine, metamfetamine

EMDIVE amfetamine, methadone

FKHAKK Amphetamin + Methamphetamin

GALBAU metamphetamine

GEIYZE Metamfetamime and Amfetamine

GTGYJT methamphetamine



Page 33 of 60

ICE 2020/1-BS


GXAXXX Methamphetamine

GYUZYX Metamphetamine

GYZBJG Amphetamine & Methamphetamine

HFZNVM Anfetamine and Metanfetamine

HJBJJZ Anphetamine and Metanphetamine

HWWFLB AMFETAMINE, METAMFETAMINE

HX3HHZ Amfetamine, Metamfetamine

IY7GAM Methamphetamine and Amphetamine

IZHTGD AMFETAMINE

J4TW7Y AMPHETAMINES

JXLWWW amfetamine, metamfetamine

MGYQGS Metanfetamina

MZ1VWF Amphetamine, Methamphetamine

NJYQDQ amphetamine, methamphetamine

OJIRJJ Metamfetamine and Amfetamine

PLCVCA METHAMPHETAMINE AMPHETAMINE

PQCCX9 Amphetamine and methamphetamine

PYGPFU Amfetamine,Metamfetamine

Q6MZSI Amfetamine and Metamfetamine

QAWYAR Amphetamine and Methamphetamine

QHSF3F METHAMPHETAMINE, AMPHETAMINE

QKN00I anfetamina y metanfetamina

QQPBQ3 Amphetamine and Methamphetamine

QSF8QS Amphetamine & Methamphetamine

RLFVLF Methamphetamine and amphetamine

S686FB Amphetamine and Methamphetamine

SEWUD2 Amphetamine and Methamphetamine

SRDSSE Metamfetamine

T99ZDI Methamphetamine and amphetamine

UUBWFO amfetamine, metamfetamine

W6QSWO Methamphetamine, Amphetamine

W72LJ2 methamphetamine and amphetamine

XA5WMW Diacetylmorphine, Cocaine,Nordazepam

XI434E amphetamine and methamphetamine

XLVKDV Metamfetamine

YBXJLV Methamphetamine

YN9NMH AMFETAMINE AND METAMFETAMINE

YXWLMW AMPHETAMINE AND METAMPHETAMINE

ZJFFFJ Amfetamine type stimulans



Page 34 of 60

ICE 2020/1-BS


Code Amfetamine Metamfetamine

0UAAAS - + METHAMPHETAMINE

11101C + +

2PU2G2 + + Metamfetamine use. Amfetamine, as the metabolite of metamfetamine was also detected.

33W3VV + + In the urine sample analyzed was detected and confirmed the presence of Anfetamine and Metanfetamine.

3HHHFH + + Amphetamine approx 0.4 mg/L Methylamphetamine approx 1.1 mg/L Morphine;total approx 0.02 mg/L

3XRTAK - + The findings confirm the prior ingestion of methamphetamine

43A63W + + sample positive for amfetamine and metamfetamine

4464E4 + + The above drugs were detected in both the preliminary screening/testing and confirmed on the Gas Chromatography Mass Spectrometry.

499391 + + Positive for amphetamine and metamphetamine

5H6VOU + + Amfetamine and metamfetamine were detected in BS-2 sample.

5MR6TM + + the sample contains Methamphetamine at a concentration of 858.6 ng/mL and Amphetamine at a concentration of 309 ng/mL

5Q55XW + + BS-2 is positive for Amphetamine & Methamphetamine

5XRKWM + + Amphetamine and Methamphetamine were detected using LC-MS-MS which indicates the presence of controlled drugs

658B75 + + Amfetamine and Metamfetamine detected

7BJIMY + + Amfetamine and Metamfetamine were detected in BS-2, 2020/1 exercise

7DD9DQ + + In sample BS-2 the drugs anfetamine and metanfetamine were detected.

7HRXA5 - + The urine sample come from metamfetamine user, also caffeine were positive in this test sample

7OQCKC + +

7V7K74 + + Amphetamine and methamphetamine were detected in BS-2 sample.



Page 35 of 60

ICE 2020/1-BS


834UF9 - -

8T88DY + +

9R5K1I + + Analytical Adverse Finding for D-amfetamine and S-methylamphetamine

A4AQON + +

AE71EE + + It was detected amphetamine and methamphetamine in this urine sample

AIWSV2 + +

ATVRVM + +

BFKQKL - +

C6P3ZC + + MA consumer

CMPLP5 + + GC/MS and HPLC/DAD

CYYURR + + We found Metamfetamine as narcotic substance and Amfetamine as metabolite in BS-02 based on INCB green list regulation

DCG2M5 + + Amfetamine and Metamfetamine were detected in sample 2020/1/BS-2.

DCGDXG + + Presence of amphetamine and metamphetamine

DKQBOL + + Amfetamine and metamfetamine are central nervous system stimulants.

EMDIVE + ANP stimulant, opioid

FKHAKK + +

GALBAU - + We found metamphetamine in the sample, and also caffeine and theobromine

GEIYZE + + gc msd

GQD911 + +

GTGYJT - + 2020/1/BS-2 urine contain methamphetamine.

GXAXXX ANP + Methamphetamine was detected in 2020/1/BS-2.

GYUZYX ANP + screening by 161 technic



Page 36 of 60

ICE 2020/1-BS


GYZBJG + + Sample 2020/1/BS-2 contains Amphetamine & Methamphetamine.

HFZNVM + + Anfetamine and Metanfetamine.

HJBJJZ + + Anphetamine and Metanphetamine.

HWWFLB + + SAMPLE 2020/1/BS-2 FOUND TO CONTAIN AMFETAMINE AND METAMFETAMINE

HX3HHZ + + -

IY7GAM + + These findings indicate the intake of methamphetamine ( amphetamine is a metabolite of methamphetamine) or the intake of both methamphetamine and amphetamine

IZHTGD + -

J4TW7Y + + AMPHETAMINE + METHAMPHETAMINE

JXLWWW ANP ANP

MGYQGS - + En la muestra analizada, se detectó Metanfetamina.

MHHRMM + +

MZ1VWF + + In the sample No. BS-2 were detected amphetamine and methamphetamine.

NJYQDQ + +

OJIRJJ + + Test sample 2020/1/BS-2 was found to contain controlled drugs for Metamfetamine and Amfetamine, therefore Positive for the Screening and Confirmatory analyses with concentration values of 732.79 ng/mL and 263.03 ng/mL, respectively.

PLCVCA + + SAMPLE INDICATES THE USE OF METHAMPETAMINE

PQCCX9 + +

PYGPFU + + Amfetamine,Metamfetamine

Q6MZSI + + Amfetamine and Metamfetamine which are stimulants were detected in this sample BS-2 . The drugs detected were also quantified

QAWYAR + + Amphetamine and Methamphetamine are stimulants. Both drugs are schedule II substances in the United States.

QHSF3F + + CAFFEINE

QKN00I + + EN la muestra analizada se identifica anfetamina y metanfetamina



Page 37 of 60

ICE 2020/1-BS


QQPBQ3 + + Screening Test using Immonuassay technique. Identification and quantitative using LC-MS and GC-MS.

QSF8QS + + Urine Drugs Screen - Amphetamine Present Indicated Urine Drugs Screen - Methamphetamine Present Indicated Amphetamine and methamphetamine may be present as drugs in their own right or as metabolites of other drugs such as MDMA. [Waluba, A. and Seger, D. (1999) Human and Experimental Toxicology, 18, pp.119-125].

REAZAR - - qualitative assay : amphetamines

RLFVLF + + Methamphetamine and amphetamine detected. Amphetamine is a metabolite of methamphetamine.

S686FB + +

SEWUD2 + + Amphetamine and Methamphetamine detected

SRDSSE - +

T99ZDI + + Both are illicit drugs, methamphetamine metabolize into amphetamine. Those two molecules are central nervous system stimulants. Their absorption results in an intellectual excitement, motor hyperactivity with insomnia and absence of a feeling of fatigue, increased vigilance, a feeling of well-being and self-confidence

UUBWFO + +

VZZCZZ + +

W4HPDB + +

W6QSWO + +

W72LJ2 + +

X2IWBU - +

XA5WMW - - Diacetylmorphine and cocaine were detected in the sample.

XI434E + + this person consumed methamphetamine or amphetamine and metamphetamine

XLVKDV - +

YBXJLV ANP + Methamphetamine in concentration of 432.62 ng/mL

YN9NMH + + AMFETAMINE AND METAMFETAMINE WERE DETECTED



Page 38 of 60

ICE 2020/1-BS


YXWLMW + + IN URINE WAS FOUND AMPHETAMINE AND METAMPHETAMINE

ZJFFFJ + + Amfetamine, Metamfetamine



Page 39 of 60

ICE 2020/1-BS



Code 100 110 120 140 150 160 161 170 180 230 231 210

0UAAAS SI I I


2PU2G2 I I SI

33W3VV SI I

3HHHFH S I I

3XRTAK I SI



499391 S I



5Q55XW S I I I

5XRKWM S I I

658B75 I

7BJIMY SI I SI

7DD9DQ SI SI

7HRXA5 SI

7OQCKC S I

7V7K74 I

834UF9 S I SI

8T88DY I

9R5K1I SI SI



AIWSV2 I

ATVRVM I I S

BFKQKL S I I

C6P3ZC SI


CYYURR S I I

DCG2M5 SI




Page 40 of 60

ICE 2020/1-BS

Code 100 110 120 140 150 160 161 170 180 230 231 210

DCGDXG S SI SI I

DKQBOL I I

EMDIVE S I


GALBAU SI I

GEIYZE S I

GQD911 S I


GXAXXX S I

GYUZYX S I SI

GYZBJG I

HFZNVM I

HJBJJZ I

HWWFLB SI

HX3HHZ SI I

IY7GAM S I SI

IZHTGD S I I

J4TW7Y S I SI

MGYQGS I I

MHHRMM S I I

MZ1VWF S I SI

NJYQDQ S I S

OJIRJJ I S DTK

PLCVCA S I

PQCCX9 SI


Q6MZSI S I I

QAWYAR I LC-QTOF

QHSF3F S I I

QKN00I S I I

QQPBQ3 S I

QSF8QS I

REAZAR S I

RLFVLF S I


SEWUD2 SI

SRDSSE SI I



Page 41 of 60

ICE 2020/1-BS

Code 100 110 120 140 150 160 161 170 180 230 231 210

T99ZDI S I I I

UUBWFO I I S Cobas

VZZCZZ SI

W4HPDB S I I

W6QSWO SI

W72LJ2 SI

X2IWBU S I I

XA5WMW S I

XI434E S I I

XLVKDV I I

YBXJLV S I

YN9NMH S I SI

YXWLMW SI




Page 42 of 60

ICE 2020/1-BS



0UAAAS CANNABINOIDS

11101C 11-nor-∆9-THC-9-carboxylic acid

2PU2G2 carboxy-THC

33W3VV 11-nor-delta9-THC-9-carboxylic acid

3HHHFH THC-COOH, Morphine(total)

3XRTAK THC-COOH

43A63W 11-nor-∆9-THC-9-carboxylic acid

4464E4 THC (Tetrahydrocannabinol)

499391 THC-COOH

5H6VOU 11-nor-∆9-THC-9-carboxylic acid

5MR6TM THCCOOH

5Q55XW 11-nor delta-9-THC-carboxylic acid

5XRKWM THCA

7BJIMY 11-nor-∆9-THC-9-carboxylic acid

7DD9DQ 11-nor-Δ-THC-9-carboxylic acid

7HRXA5 11-Hydroxy delta 9 tetrahydrocannabinol

7OQCKC 11-nor-∆9-THC-9-carboxylic acid

7V7K74 THC-COOH

834UF9 11-nor-9-THC-9-carboxylic acid

9R5K1I 11-nor-delta9-THC-9-carboxylic acid

AE71EE THC-COOH

AIWSV2 Tetrahydrocannabinol

BFKQKL 11-nor-d9-THC-9-carboxilic acid

C6P3ZC THC-COOH

CMPLP5 11-nor-delta9-THC-9-carboxylic acid

CYYURR 11-nor-∆9-THC-9-carboxylic acid

DCG2M5 11-nor-∆9-THC-9-carboxylic acid

DCGDXG THCCOOH

EMDIVE THCA

FKHAKK THC-COOH

GALBAU 11-nor-d9-THC-9-carboxylic acid

GEIYZE 11-nor-∆9-THC-9-carboxylic acid

GTGYJT tetrahidrocannabinolic acid

GXAXXX 11-Nor-delta-9-THC-9-carboxylic acid

GYUZYX 11-nor-∆9-THC-9-carboxylic acid


HFZNVM 11-nor-delta9-THC-9-carboxylic acid



Page 43 of 60

ICE 2020/1-BS


HJBJJZ Tetrahydrocannabinol-COOH

HWWFLB NONE

HX3HHZ 11-nor-∆9-THC-9-carboxylic acid

IY7GAM 11-nor-∆9-THC-9-carboxylic acid

IZHTGD THC-COOH

J4TW7Y THC

JXLWWW 11-nor-d9-THC-9-carboxylic acid

MGYQGS THC-COOH

MZ1VWF THC-COOH

NJYQDQ thcc

OJIRJJ 11-nor-∆9-THC-9-carboxylic acid

PLCVCA THCCOOH PARACETAMOL

PYGPFU 11-nor-∆9-THC-9-carboxylic acid

Q6MZSI Cannabinoid

QHSF3F THC-COOH

QKN00I THCCOOH

QQPBQ3 11-nor-∆9-THC-9-carboxylic acid

QSF8QS THC-COOH

RLFVLF 11-nor-delta-9-THC-9-COOH

S686FB 11-nor-∆9-THC-9-carboxylic acid

SEWUD2 -

SRDSSE 11-nor-∆9-THC-9-carboxylic acid

T99ZDI THC-COOH

UUBWFO 11-nor-∆9-THC-9-carboxylic acid

W6QSWO THC-COOH

W72LJ2 11-nor-∆9-THC-9-carboxylic acid

XA5WMW Diacetylmorphine, 11 Nor delta 9 THC, Cocaine

XI434E 11-nor-∆9-THC-9-carboxylic acid

XLVKDV 11-nor-∆9-THC-9-carboxylic acid

YBXJLV Carboxilic Acid 11 nor Delta 9 THC

YN9NMH 11-NOR-DELTA-9-THC-9- CARBOXYLIC ACID

YXWLMW COOH-THC

ZJFFFJ Cannabinoids



Page 44 of 60

ICE 2020/1-BS


Code 11-nor-∆9-THC-9-carboxylic acid

0UAAAS + THC-COOH

11101C +

2PU2G2 + Use of Cannabis or Dronabinol.

33W3VV + In the urine sample analyzed was detected and confirmed the presence of 11-nor-delta9-THC-9- carboxylic acid.

3HHHFH + THC-COOH approx 250 ng/mL Morphine, total approx 0.02 mg/L

3XRTAK + The findings confirm the prior active use of cannabis

43A63W + sample positive for 11-nor-∆9-THC-9-carboxylic acid

4464E4 + Th drug was detected in both the preliminary screening/testing and was confirmed on the Liquid Chromatography Tandem Mass Spectrometry.

499391 + Positive for THC-COOH

5H6VOU + 11-nor-∆9-THC-9-carboxylic acid was detected in BS-3 sample.

5MR6TM + The sample contains THCCOOH the major metabolite of THC (delta-9- tetrahydrocannabinol)

5Q55XW + BS-3 is positive for 11-nordelta-9-THC-carboxylic acid

5XRKWM + THCA were detected using GC-MS which indicates the presence of controlled drugs

658B75 ANP Common drugs not detected

7BJIMY + 11-nor-∆9-THC-9-carboxylic acid was detected in BS-3, 2020/1 exercise

7DD9DQ + In sample BS-3 the metabolite 11-nor-Δ-THC-9-carboxylic acid was detected.

7HRXA5 + The found drug is metabolite used as a biomarker for marijuana user

7OQCKC + Cannabis consumption

7V7K74 + 11-Nor Delta-9-Tetrahydrocannabinol (THC-COOH) was detected in BS-3 sample.

834UF9 -

8T88DY ANP



Page 45 of 60

ICE 2020/1-BS


9R5K1I + Analytical Adverse Finding for THCA.

A4AQON +

AE71EE + It was detected a THC metabolite in this urine sample

AIWSV2 +

ATVRVM ANP

BFKQKL +

C6P3ZC + cannabis consumer

CMPLP5 + GC/MS

CYYURR + We found 11-nor-∆9-THC-9-carboxylic acid in BS-03 as narcotic substance based on INCB green list regulation

DCG2M5 + 11-nor-∆9-THC-9-carboxylic acid was detected in sample 2020/1/BS-3.

DCGDXG + presence of THCCOOH (> 100ng/mL)

DKQBOL - Examination and analyses performed on 2020/1/BS-3 did not reveal the presence of substances of toxicological significance

EMDIVE + cannabinoids

FKHAKK +

GALBAU + we founf 11-nor-d9-THC-9-carboxylic acid and also caffeine.

GEIYZE + cg msd

GQD911 +

GTGYJT + 2020/1/BS-3 urine contain tetrahidrocannabinolic acid.

GXAXXX + 11-Nor-delta-9-THC-9-carboxylic acid was detected in 2020/1/BS-3.

GYUZYX + THC-COOH was detected in BS3 sample by 180 technic

GYZBJG ANP No common basic and acid drugs were detected in sample 2020/1/BS-3.

HFZNVM + 11-nor-delta9-THC-9-carboxylic acid.



Page 46 of 60

ICE 2020/1-BS


HJBJJZ + Tetrahydrocannabinol-COOH

HWWFLB ANP SAMPLE 2020/1/BS-3 FOUND NOT TO CONTAIN ANY DRUGS

HX3HHZ + -

IY7GAM + It indicates the intake of cannabis.

IZHTGD +

J4TW7Y + 11-NOR-DELTA9-THC-CARBOXILICO

JXLWWW ANP only free THC-COOH was measured

MGYQGS + En la muestra analizada, se detectó THC-COOH.

MHHRMM +

MZ1VWF + In the sample No. BS-3 was detected THC-COOH.

NJYQDQ +

OJIRJJ + Test sample 2020/1/BS-3 was found to contain controlled drugs for 11-nor-∆9-THC-9-carboxylic acid, therefore Positive for the Screening and Confirmatory analyses with concentration value of 216.14 ng/mL.

PLCVCA + THCCOOH IS A METABOLITE OF THC WHICH IS THE ACTIVE PHCYCHOTROPIC SUBSTANCE OF CANNABIS SATIVA SAMPLE INDICATES THE USE OF CANNABIS PARACETAMOL IS AN ANALGESIC MEDICATION

PQCCX9 -

PYGPFU + 11-nor-∆9-THC-9-carboxylic acid

Q6MZSI + (+)- 11-nor-9-carboxydelta9-THC was detected in this sample BS-3 . The drug detected was also quantified

QAWYAR ANP

QHSF3F + CAFFEINE

QKN00I ANP En la muestra analizada se identifica cannabinoides (THCCOOH)

QQPBQ3 + Screening Test using Immonuassay technique. Identification and quantitative using GC-MS.



Page 47 of 60

ICE 2020/1-BS


QSF8QS + Urine Drugs Screen - THC-COOH Present Indicated THC-COOH (delta-9-THC-Carboxylic Acid) is a major metabolite of delta THC, which is the most psychoactive of the principle constituents of Marijuana. [Baselt R.C., Disposition of Toxic Drugs and Chemicals in Man, 11th Ed, 2017

REAZAR ANP qualitative assay : cannabis

RLFVLF + 11-nor-delta-9-THC-9-COOH detected.

S686FB +

SEWUD2 ANP no common drugs detected

SRDSSE +

T99ZDI + Cannabis is the most widely used illicit drug in many countries around the world , and is the most commonly detected drug of abuse in workplace urine drug tests. Δ9-tetrahydrocannabinol (THC), the major psychoactive component of cannabis, is rapidly metabolized to the inactive metabolite THCCOOH, conjugated with glucuronic acid, and excreted in urine

UUBWFO +

VZZCZZ +

W4HPDB +

W6QSWO + Indicative of cannabis consumption

W72LJ2 +

X2IWBU +

XA5WMW + Diacetylmorphine, 11 nor delta 9 THC and Cocaine were detected in the sample.

XI434E + this person consumed cannabis and/or cannabis resin

XLVKDV +

YBXJLV + The Method Used for the analysis of the sample show good yield and performance

YN9NMH + 11-NOR-DELTA-9-THC-9- CARBOXYLIC ACID WAS DETECTED

YXWLMW + IN URINE WAS FOUND COOH-THC

ZJFFFJ + 11-nor-∆9-THC-9-carboxylic acid



Page 48 of 60

ICE 2020/1-BS



Code 100 110 120 140 150 160 161 170 180 230 231 210

0UAAAS SI I I


2PU2G2 I I SI

33W3VV SI I

3HHHFH S I I

3XRTAK I SI



499391 S I



5Q55XW S I I I

5XRKWM S I I

658B75 I

7BJIMY SI I SI

7DD9DQ SI SI

7HRXA5 SI

7OQCKC S I

7V7K74 I

834UF9 S I SI

8T88DY I

9R5K1I SI SI



AIWSV2 I

ATVRVM I I S

BFKQKL S I I

C6P3ZC SI


CYYURR S I I

DCG2M5 SI




Page 49 of 60

ICE 2020/1-BS

Code 100 110 120 140 150 160 161 170 180 230 231 210

DCGDXG S SI SI I

DKQBOL I I

EMDIVE S I


GALBAU SI I

GEIYZE S I

GQD911 S I


GXAXXX S I

GYUZYX S I SI

GYZBJG I

HFZNVM I

HJBJJZ I

HWWFLB SI

HX3HHZ SI I

IY7GAM S I SI

IZHTGD S I I

J4TW7Y S I SI

MGYQGS I I

MHHRMM S I I

MZ1VWF S I SI

NJYQDQ S I S

OJIRJJ I S DTK

PLCVCA S I

PQCCX9 SI


Q6MZSI S I I

QAWYAR I LC-QTOF

QHSF3F S I I

QKN00I S I I

QQPBQ3 S I

QSF8QS I

REAZAR S I

RLFVLF S I


SEWUD2 SI

SRDSSE SI I



Page 50 of 60

ICE 2020/1-BS

Code 100 110 120 140 150 160 161 170 180 230 231 210

T99ZDI S I I I

UUBWFO I I S Cobas

VZZCZZ SI

W4HPDB S I I

W6QSWO SI

W72LJ2 SI

X2IWBU S I I

XA5WMW S I

XI434E S I I

XLVKDV I I

YBXJLV S I

YN9NMH S I SI

YXWLMW SI




Page 51 of 60

ICE 2020/1-BS



0UAAAS OPIATES

11101C Morphine

2PU2G2 morphine

33W3VV Morphine

3HHHFH Morphine, total

3XRTAK Total (free and glucuronide conjugated) morphine

43A63W morphine (total)

4464E4 Morphine

499391 Morphine

5H6VOU Morphine

5MR6TM Morphine

5Q55XW Morphine

5XRKWM Morphine

7BJIMY Morphine

7DD9DQ Morphine

7HRXA5 Morphine

7OQCKC Morphine

7V7K74 Morphine

834UF9 morphine

9R5K1I morphine

AE71EE Morphine, hydromorphone

AIWSV2 Morphine

ATVRVM Morphine

BFKQKL Morphine

C6P3ZC morphine

CMPLP5 Morphine

CYYURR Morphine

DCGDXG morphine

EMDIVE codeine, morfine, 6-MAM

FKHAKK Morphine

GALBAU morphine

GEIYZE Morphine (Total)

GTGYJT codeine

GXAXXX Morphine

GYUZYX 6-Monoacetylmorphine (6-MAM


HFZNVM Morphine



Page 52 of 60

ICE 2020/1-BS


HJBJJZ Morphine

HWWFLB NONE

HX3HHZ Morphine

IY7GAM Morphine

IZHTGD MORPHINE

J4TW7Y OPIATES+ OTHERS

JXLWWW Morphine

MGYQGS Morfina

MZ1VWF Morphine (total)

NJYQDQ morphine

PLCVCA MORPHINE

PQCCX9 morphine

PYGPFU Morphine

Q6MZSI Opiate/Opioid

QAWYAR Morphine

QHSF3F MORPHINE

QKN00I Morfina

QQPBQ3 Morphine

QSF8QS Morphine

REAZAR morphine

RLFVLF Morphine

S686FB Morphine

SEWUD2 -

SRDSSE morphine

T99ZDI Morphine

W6QSWO Morphine

W72LJ2 morphine

XA5WMW Diacetylmorphine, Nordazepam, epinephrine

XI434E Morphine

XLVKDV no

YBXJLV Morphine

YN9NMH MORPHINE

YXWLMW MORPHINE

ZJFFFJ Opiates



Page 53 of 60

ICE 2020/1-BS


Code Morphine (Total)

0UAAAS + TOTAL MORPHINE

11101C +

2PU2G2 + Probable use of medicinal morphine.

33W3VV + In the urine sample analyzed was detected and confirmed the presence of Morphine.

3HHHFH + Morphine, total Detected > 0.5 mg/L

3XRTAK + The findings demonstrate either the non-recent use of heroin/morphine or the more recent ingestion of a food product containing poppy seeds

43A63W + sample positive for morphine (total)

4464E4 + Drug was detected in the Laboratory techniques that were used that is screening using the drug kit and the Gas Chromatorphraphy Tandem Mass Spectrometry.

499391 + Positive for Morphine

5H6VOU + Morphine was detected in BS-4 sample.

5MR6TM + the sample contains Morphine at a concentration of 810.2 ng/mL

5Q55XW + BS-4 is positive for morphine

5XRKWM + Morphine were detected using GC-MS which indicates the presence of controlled drugs

658B75 ANP Common drugs not detected

7BJIMY + Morphine was detected in BS-4, 2020/1 exercise

7DD9DQ + In sample BS-4 the drug morphine (total) was detected.

7HRXA5 + The urine sample was from heroin or morphine user although biomarker for heroin user is 6- monoacetyl morphine.

7OQCKC + Morphine adminstration

7V7K74 + Morphine detected in BS-4 sample.

834UF9 -



Page 54 of 60

ICE 2020/1-BS


8T88DY ANP

9R5K1I + Analytical Adverse Finding for morphine

A4AQON +

AE71EE + It was detected morphine and metabolite in this sample

AIWSV2 +

ATVRVM +

BFKQKL +

C6P3ZC + opiates consumer

CMPLP5 + GC/MS and HPLC/DAD

CYYURR + We found Morphine as narcotic substance based on INCB yellow list regulation

DCG2M5 ANP No common drugs were detected in sample 2020/1/BS-4.

DCGDXG + presence of morphine (> 1000ng/mL)

DKQBOL - Examination and analyses performed on 2020/1/BS-4 did not reveal the presence of substances of toxicological significance

EMDIVE + opiates

FKHAKK +

GALBAU + we found morphine in the sample and also lidocaine and caffeine

GEIYZE + gc msd

GQD911 +

GTGYJT - 2020/1/BS-4 urine contain codeine.

GXAXXX + 2020/1/BS-4 contains 796 ng/mL morphine.

GYUZYX ANP the presence of 6 MAM in BS1 was identified by 161 technic

GYZBJG ANP No common basic and acid drugs were detected in sample 2020/1/BS-4.



Page 55 of 60

ICE 2020/1-BS


HFZNVM + Morphine.

HJBJJZ + Morphine.

HWWFLB ANP SAMPLE 2020/1/BS-4 FOUND NOT TO CONTAIN ANY DRUGS

HX3HHZ + -

IY7GAM + The presence of morphine indicates the intake of morphine or the past exposure to heroin.

IZHTGD +

J4TW7Y - MORPHINE+ ASENAPINE

JXLWWW ANP only free Morphine was measured

MGYQGS + En la muestra analizada, se detectó Morfina.

MHHRMM +

MZ1VWF + In the sample No. BS-4 was detected morphine (total).

NJYQDQ +

OJIRJJ ANP Test sample 2020/1/BS-4 was Screened POSITIVE for controlled drugs OPIATES/OPIOIDS using immunoassay technique/drug test kit. However, confirmatory analyses was not able to perform.

PLCVCA + THE PRESENCE OF MORPHINE ONLY, IN THE SPECIFIC SAMPLE INDICATES THE USE OF MORPHINE AS AN OPIATE ANALGESIC MEDICATION MORPHINE IS ALSO ACTIVE METABOLITE OF DIACETYLMORPHINE AND CODEINE

PQCCX9 +

PYGPFU + Morphine

Q6MZSI + Morphine and Hydromorphone were detected in this sample, BS-4, they were quantified too

QAWYAR + Morphine is a narcotic analgesic found in the opium poppy. It is a schedule II substances in the United States.

QHSF3F + CAFFEINE

QKN00I + En la muestra analizada se identifica morfina

QQPBQ3 + Screening Test using Immonuassay technique. Identification and quantitative using GC-MS.



Page 56 of 60

ICE 2020/1-BS


QSF8QS + Urine Drugs Screen - Morphine Present Indicated

Morphine may be present in urine as a result of intake of morphine (including medicinal preparations containing morphine), or heroin (diacetylmorphine) which metabolises to 6- monoacetylmorphine and then morphine, or pholcodine which metabolises to morphine, or codeine which is biotransformed in man to morphine and norcodeine. After codeine administration however, the urinary total codeine/total morphine concentration ratio generally exceeds 1 for the first 24 hours, i.e. there will be more total codeine present than total morphine. After 30 hours only morphine may be detectable in urine. Also, eating of poppyseed foods can result in urine morphine levels as high as 4.5ug/mL. [R.C. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 11th Ed. 2017]

REAZAR +

RLFVLF + Morphine detected.

S686FB +

SEWUD2 ANP no common drugs detected

SRDSSE +

T99ZDI + Morphine is a pain medication (analgesic effect) of the opiate family. Morphine is an alkaloid molecule extracted from opium. It acts directly on the central nervous system to decrease the feeling of pain.

UUBWFO -

VZZCZZ +

W4HPDB +

W6QSWO + Indicative of opioid consumption* * Please note that the presence of morphine in urine may occur as a result of the consumption of poppy seed products, medications containing codeine and/or morphine, or illicit drugs.

W72LJ2 +

X2IWBU +

XA5WMW + Diacetylmorphine was detected in the sample.

XI434E + this person consumed morphine or poppy seeds

XLVKDV -

YBXJLV + The Used method for the analysis of sample show agood yield and performance



Page 57 of 60

ICE 2020/1-BS


YN9NMH + MORPHINE WAS DETECTED

YXWLMW + IN URINE WAS FOUND MORPHINE

ZJFFFJ + Morphine



Page 58 of 60

ICE 2020/1-BS



Code 100 110 120 140 150 160 161 170 180 230 231 210

0UAAAS SI I I


2PU2G2 I I SI

33W3VV SI I

3HHHFH S I I

3XRTAK I SI



499391 S I



5Q55XW S I I I

5XRKWM S I I

658B75 I

7BJIMY SI I SI

7DD9DQ SI SI

7HRXA5 SI

7OQCKC S I

7V7K74 I

834UF9 S I SI

8T88DY I

9R5K1I SI SI



AIWSV2 I

ATVRVM I I S

BFKQKL S I I

C6P3ZC SI


CYYURR S I I

DCG2M5 SI




Page 59 of 60

ICE 2020/1-BS

Code 100 110 120 140 150 160 161 170 180 230 231 210

DCGDXG S SI SI I

DKQBOL I I

EMDIVE S I


GALBAU SI I

GEIYZE S I

GQD911 S I


GXAXXX S I

GYUZYX S I SI

GYZBJG I

HFZNVM I

HJBJJZ I

HWWFLB SI

HX3HHZ SI I

IY7GAM S I SI

IZHTGD S I I

J4TW7Y S I SI

MGYQGS I I

MHHRMM S I I

MZ1VWF S I SI

NJYQDQ S I S

OJIRJJ I S DTK

PLCVCA S I

PQCCX9 SI


Q6MZSI S I I

QAWYAR I LC-QTOF

QHSF3F S I I

QKN00I S I I

QQPBQ3 S I

QSF8QS I

REAZAR S I

RLFVLF S I


SEWUD2 SI

SRDSSE SI I



Page 60 of 60

ICE 2020/1-BS

Code 100 110 120 140 150 160 161 170 180 230 231 210

T99ZDI S I I I

UUBWFO I I S Cobas

VZZCZZ SI

W4HPDB S I I

W6QSWO SI

W72LJ2 SI

X2IWBU S I I

XA5WMW S I

XI434E S I I

XLVKDV I I

YBXJLV S I

YN9NMH S I SI

YXWLMW SI


Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria

Tel. : (+43-1) 26060-0, Fax : (+43-1) 26060-5866, www.unodc.org

Documents

INTERNATIONAL COLLABORATIVE EXERCISES (ICE) · any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city